Heliyon,
Год журнала:
2024,
Номер
10(13), С. e34243 - e34243
Опубликована: Июль 1, 2024
With
the
rapid
development
of
biotechnology,
long
non-coding
RNAs
(lncRNAs)
have
shown
promising
potential
for
cancer
treatment
and
may
become
novel
therapeutic
targets.
This
study
aimed
to
explore
roles
lncRNAs
in
retinoblastoma
(RB).
It
involves
analysing
differentially
expressed
RB
normal
tissues
from
GSE111168
GSE125903
datasets,
further
validating
them
cells.
Our
findings
determined
that
lncRNA
MIMT1
was
upregulated
cell
lines
tissues.
In
WERI-Rb1
Y79
cells,
silencing
significantly
inhibited
proliferation,
whereas
overexpression
enhanced
proliferation.
Furthermore,
vivo
xenograft
experiments
demonstrated
knockdown
suppressed
tumour
volume
weight.
Subsequent
mechanistic
investigations
showed
upregulates
fibroblast
expression
FGF2
by
binding
miR-153-5p,
ultimately
promoting
suggest
functions
as
an
oncogene
potentially
serves
a
molecular
marker
diagnostic
prognostic
assessments.
Thus,
MIMT1/miR-153-5p/FGF2
pathway
is
target
treatment.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Ноя. 26, 2024
Epigenetics
governs
a
chromatin
state
regulatory
system
through
five
key
mechanisms:
DNA
modification,
histone
RNA
remodeling,
and
non-coding
regulation.
These
mechanisms
their
associated
enzymes
convey
genetic
information
independently
of
base
sequences,
playing
essential
roles
in
organismal
development
homeostasis.
Conversely,
disruptions
epigenetic
landscapes
critically
influence
the
pathogenesis
various
human
diseases.
This
understanding
has
laid
robust
theoretical
groundwork
for
developing
drugs
that
target
epigenetics-modifying
pathological
conditions.
Over
past
two
decades,
growing
array
small
molecule
targeting
such
as
methyltransferase,
deacetylase,
isocitrate
dehydrogenase,
enhancer
zeste
homolog
2,
have
been
thoroughly
investigated
implemented
therapeutic
options,
particularly
oncology.
Additionally,
numerous
epigenetics-targeted
are
undergoing
clinical
trials,
offering
promising
prospects
benefits.
review
delineates
epigenetics
physiological
contexts
underscores
pioneering
studies
on
discovery
implementation
drugs.
include
inhibitors,
agonists,
degraders,
multitarget
agents,
aiming
to
identify
practical
challenges
avenues
future
research.
Ultimately,
this
aims
deepen
epigenetics-oriented
strategies
further
application
settings.
International Journal of Surgery,
Год журнала:
2024,
Номер
unknown
Опубликована: Апрель 23, 2024
Neoadjuvant
and
adjuvant
immunotherapies
for
cancer
have
evolved
through
a
series
of
remarkable
critical
research
advances;
however,
addressing
their
similarities
differences
is
imperative
in
clinical
practice.
Therefore,
this
study
aimed
to
examine
from
the
perspective
informatics
analysis.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(3), С. 1942 - 1942
Опубликована: Фев. 5, 2024
MicroRNAs
(miRNAs)
are
19-23
nucleotide
long,
evolutionarily
conserved
noncoding
RNA
molecules
that
regulate
gene
expression
at
the
post-transcriptional
level.
In
this
review,
involvement
of
miRNAs
is
summarized
in
differentiation
and
function
immune
cells,
anti-infective
responses,
immunodeficiencies
autoimmune
diseases.
Roles
anticancer
immunity
transplantation
solid
organs
hematopoietic
stem
cells
also
discussed.
Major
focus
put
on
translational
clinical
applications
miRNAs,
including
establishment
noninvasive
biomarkers
for
differential
diagnosis
prediction
prognosis.
Patient
selection
response
to
biological
therapy
one
most
promising
fields
application.
Replacement
or
inhibition
has
enormous
therapeutic
potential,
with
constantly
expanding
possibilities.
Although
important
challenges
still
await
solutions,
evaluation
miRNA
fingerprints
may
contribute
an
increasingly
personalized
management
dysregulation
a
remarkable
reduction
toxicity
treatment
side
effects.
More
detailed
knowledge
molecular
effects
physical
exercise
nutrition
system
facilitate
self-tailored
lifestyle
recommendations
advances
prevention.
International Journal of Nanomedicine,
Год журнала:
2024,
Номер
Volume 19, С. 4803 - 4834
Опубликована: Май 1, 2024
Abstract:
The
utilization
of
PD-1/PD-L1
inhibitors
marks
a
significant
advancement
in
cancer
therapy.
However,
the
efficacy
monotherapy
is
still
disappointing
substantial
subset
patients,
necessitating
exploration
combinational
strategies.
Emerging
from
promising
results
KEYNOTE-942
trial,
RNA-based
therapies,
particularly
circRNAs
and
piRNAs,
have
distinguished
themselves
as
innovative
sensitizers
to
immune
checkpoint
(ICIs).
These
non-coding
RNAs,
notable
for
their
stability
specificity,
were
once
underrecognized
but
are
now
known
crucial
roles
regulating
PD-L1
expression
bolstering
anti-cancer
immunity.
Our
manuscript
offers
comprehensive
analysis
selected
elucidating
immunomodulatory
effects
mechanisms,
thus
underscoring
potential
ICIs
enhancers.
In
conjunction
with
recent
Nobel
Prize-awarded
advancements
mRNA
vaccine
technology,
our
review
highlights
transformative
implications
these
findings
treatment.
We
also
discuss
prospects
piRNAs
future
therapeutic
applications
research.
This
study
pioneers
synergistic
application
novel
augment
inhibition
therapy,
demonstrating
unique
modulating
responses.
offer
groundbreaking
approach
enhancing
immunotherapy,
opening
new
avenues
treatment
abstract
aims
encapsulate
essence
research
burgeoning
role
RNAs
encouraging
further
investigation
into
this
field.
Keywords:
CircRNA,
piwi-RNA,
blockade,
immunotherapy
sensitizer,
combination
therapy
Abstract
The
integration
of
liquid
biopsy
with
epigenetic
markers
offers
significant
potential
for
early
lung
cancer
detection
and
personalized
treatment.
Epigenetic
alterations,
including
DNA
methylation,
histone
modifications,
noncoding
RNA
changes,
often
precede
genetic
mutations
are
critical
in
progression.
In
this
study,
we
explore
how
biopsy,
combined
markers,
can
provide
cancer,
potentially
predicting
onset
up
to
4
years
before
clinical
diagnosis.
We
discuss
the
challenges
targeting
regulators,
which
could
disrupt
cellular
balance
if
overexploited,
need
maintaining
key
gene
expressions
therapeutic
applications.
This
review
highlights
promise
using
early‐stage
diagnosis,
a
focus
on
optimizing
treatment
strategies
precision
medicine.
Abstract
Background
Recent
evidence
has
demonstrated
that
abnormal
expression
and
regulation
of
circular
RNA
(circRNAs)
are
involved
in
the
occurrence
development
a
variety
tumors.
The
aim
this
study
was
to
investigate
effects
circ_PPAPDC1A
Osimertinib
resistance
NSCLC.
Methods
Human
circRNAs
microarray
analysis
conducted
identify
differentially
expressed
(DE)
Osimertinib-acquired
tissues
effect
on
cell
proliferation,
invasion,
migration,
apoptosis
assessed
both
vitro
vivo.
Dual-luciferase
reporter
assay,
RT-qPCR,
Western-blot,
rescue
assay
were
employed
confirm
interaction
between
circ_PPAPDC1A/miR-30a-3p/IGF1R
axis.
Results
results
revealed
significantly
upregulated
acquired
reduced
sensitivity
PC9
HCC827
cells
promoted
while
inhibiting
Osimertinib-resistant
PC9/OR
HCC829/OR
cells,
Silencing
partially
reversed
resistance.
Additionally,
acted
as
competing
endogenous
(ceRNA)
by
targeting
miR-30a-3p,
Insulin-like
Growth
Factor
1
Receptor
(IGF1R)
identified
functional
gene
for
miR-30a-3p
Furthermore,
confirmed
axis
plays
role
activating
PI3K/AKT/mTOR
signaling
pathway
NSCLC
with
Conclusions
Therefore,
first
time
we
exerts
an
oncogenic
sponging
active
IGF1R/PI3K/AKT/mTOR
pathway.
may
serve
novel
diagnostic
biomarker
therapeutic
target
patients
Graphical
Frontiers in Oncology,
Год журнала:
2024,
Номер
13
Опубликована: Янв. 4, 2024
Mesenchymal
stem
cells
(MSCs)
have
tumor-homing
ability
and
play
critical
roles
in
tumor
treatment,
but
their
dual
influences
on
progression
limit
therapeutic
applications.
Exosomes
derived
from
MSCs
(MSC-exosomes)
exhibit
great
potential
targeted
treatment
due
to
advantages
of
high
stability,
low
immunogenicity,
good
biocompatibility,
long
circulation
time
homing
characteristics.
Furthermore,
the
artificial
modification
MSC-exosomes
could
amplify
inhibitory
effect
tumors
overcome
tumor-promoting
effect.
In
this
review,
we
summarize
latest
strategies
involving
artificially
modified
including
employing
these
exosomes
as
nanomaterials
carry
noncoding
RNAs
or
inhibitors
anticancer
drugs,
genetic
engineering
MSC-exosomes.
We
also
discuss
feasibility
utilizing
an
emerging
cell-free
method
for
related
challenges.
